Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MAP2K1 L98_K104delinsQ |
| Therapy | U0126 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MAP2K1 L98_K104delinsQ | Advanced Solid Tumor | resistant | U0126 | Preclinical - Cell culture | Actionable | In a preclinical study, U0126 treatment failed to inhibit activation of Mek and Erk in human cells expressing MAP2K1 L98_K104delinsQ in culture (PMID: 29768711). | 29768711 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29768711) | Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis. | Full reference... |